GSK: Zantac settlements hit profit but guidance unchanged October 30, 2024 Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged. Operating profit fell by 86 per cent, and earnings per share slumped due to a settlement charge of £1.8bn related to the Zantac lawsuits. The lawsuits arose [...]
GSK shares rise after £1.7bn Zantac settlement October 10, 2024 GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]
Pharma giants GSK, Pfizer and Sanofi granted supreme court hearing in Zantac cancer lawsuits August 28, 2024 Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical giants to throw out over 70,000 lawsuits alleging that the now-discontinued heartburn drug Zantac caused cancer. The companies, which also include Pfizer and Sanofi, are challenging a lower court ruling that allowed expert testimony claiming Zantac causes cancer – a link [...]
GSK receives US breakthrough therapy designation for lung cancer treatment August 20, 2024 Pharmaceutical group GSK has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for a key lung cancer treatment. The breakthrough therapy designation is designed to expedite the development and review of drugs with the potential to treat a serious condition. Only treatments that are shown to offer a substantial improvement [...]
GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer August 6, 2024 GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.
GSK: Pharma giant raises guidance after second quarter sales give shot in the arm July 31, 2024 London-listed pharma giant GSK has raised its guidance after a strong second quarter beat market expectations, boosted by its cancer and HIV portfolio. Total sales in the second quarter of 2024 reached £7.9bn, an increase of 13 per cent year on year. Core operating profit at the pharma company rose by 18 per cent on [...]
Consumer confidence hit highest level in three years July 19, 2024 Consumer confidence has risen to its highest level in three years in a tentative sign that the economy is leaving the cost-of-living crisis behind, new data from Deloitte shows. In its latest quarterly Consumer Tracker survey, Deloitte found that sentiment grew by 6.8 per cent year on year, boosted by a significant improvement in sentiment [...]
GSK moves into New Oxford Street office in boost for central London July 16, 2024 GSK has opened the doors to its new West End office - called the Earnshaw.
GSK to pay Curevac £1.2bn for full rights to develop and commercialise mRNA vaccines July 3, 2024 GSK will assume full control of developing and manufacturing the candidate vaccines and will have worldwide rights to commercialise them.
US drug giant Pfizer beats GSK to UK government contract for 4.9m vaccine shots June 25, 2024 Pfizer has beaten GSK to win a contract to supply millions of doses of a new respiratory vaccine in the UK after the government snubbed the local drugmaker.